Comparison
DSIP vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
396091-73-9
Molecular weight
848.81 g/mol
1047.21 g/mol
Half-life
0.1 h
no data
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Gluno data
Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
1
of which in humans
1
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between DSIP and Pasireotid?
- DSIP is classified as "Research other", while Pasireotid is classified as "Research other". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Pasireotid?
- The highest available evidence level is "Human trial" for DSIP and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Pasireotid in Germany and the United States?
- Germany: DSIP — Unapproved, Pasireotid — Prescription. United States: DSIP — Unapproved, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.